CoChat
Sign Up
Cited by 1,545Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Open access
Muller, Patricia A.J., Vousden, Karen H.·2014·Cancer Cell
DOI 10.1016/j.ccr.2014.01.021PMC PMC3970583
Open this paper in CoChat — free accountOpen PDF

Abstract

Many different types of cancer show a high incidence of TP53 mutations, leading to the expression of mutant p53 proteins. There is growing evidence that these mutant p53s have both lost wild-type p53 tumor suppressor activity and gained functions that help to contribute to malignant progression. Understanding the functions of mutant p53 will help in the development of new therapeutic approaches that may be useful in a broad range of cancer types.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.01.021

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Various strategies have been explored to induce/reactivate wild type p53 or inhibit GOF mut-p53 in a wide range of cancer types, including glioblastoma.

    “Various strategies have been explored to induce/reactivate wt-p53 or inhibit GOF mut-p53 in a wide range of cancer types, including GBM [113].”

    From The p53 Pathway in Glioblastoma (2018) · cites this paper as [113]

    The section “Therapeutic Strategies to Restore Wild-Type Activity to Mutant p53” describes several approaches to reactivate p53, and “Targeting Mutant p53 Regulated Pathways” describes an approach to block mutant p53’s oncogenic effects. The GBM-specific example in “Future Directions” is a computational search for potential synthetic-lethal targets using GBM project data; it does not show that p53-reactivation or GOF-inhibition strategies were explored as treatments in GBM. Page numbers are not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 158

  1. Acin S. Li Z. Mejia O. Roop D.R. El-Naggar A.K. Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras J. Pathol. 225 2011 479 489 21952947 PMC4302750
  2. Addadi Y. Moskovits N. Granot D. Lozano G. Carmi Y. Apte R.N. Neeman M. Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner Cancer Res. 70 2010 9650 9658 20952507 PMC2999653
  3. Adorno M. Cordenonsi M. Montagner M. Dupont S. Wong C. Hann B. Solari A. Bobisse S. Rondina M.B. Guzzardo V. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis Cell 137 2009 87 98 19345189
  4. Agapova L.S. Ilyinskaya G.V. Turovets N.A. Ivanov A.V. Chumakov P.M. Kopnin B.P. Chromosome changes caused by alterations of p53 expression Mutat. Res. 354 1996 129 138 8692199
  5. Ali A. Wang Z. Fu J. Ji L. Liu J. Li L. Wang H. Chen J. Caulin C. Myers J.N. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells Nature communications 4 2013 2667 PMC3876931 24157709
  6. Atema A. Chène P. The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers Cancer Lett. 185 2002 103 109 12142085
  7. Bhowmick N.A. Neilson E.G. Moses H.L. Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337 15549095 PMC3050735
  8. Blandino G. Levine A.J. Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene 18 1999 477 485 9927204
  9. Boeckler F.M. Joerger A.C. Jaggi G. Rutherford T.J. Veprintsev D.B. Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Proc. Natl. Acad. Sci. USA 105 2008 10360 10365 18650397 PMC2492497
  10. Bossi G. Lapi E. Strano S. Rinaldo C. Blandino G. Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression Oncogene 25 2006 304 309 16170357
  11. Bossi G. Marampon F. Maor-Aloni R. Zani B. Rotter V. Oren M. Strano S. Blandino G. Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy Cell Cycle 7 2008 1870 1879 18594199
  12. Bougeard G. Sesboüé R. Baert-Desurmont S. Vasseur S. Martin C. Tinat J. Brugières L. Chompret A. de Paillerets B.B. Stoppa-Lyonnet D. French LFS working group Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families J. Med. Genet. 45 2008 535 538 18511570
  13. Braicu C. Pileczki V. Irimie A. Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells Mol. Cell. Biochem. 381 2013 61 68 23881244
  14. Brázdová M. Navrátilová L. Tichý V. Nĕmcová K. Lexa M. Hrstka R. Pečinka P. Adámik M. Vojtesek B. Paleček E. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells PLoS ONE 8 2013 e59567 23555710 PMC3608670
  15. Buganim Y. Kalo E. Brosh R. Besserglick H. Nachmany I. Rais Y. Stambolsky P. Tang X. Milyavsky M. Shats I. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction Cancer Res. 66 2006 10750 10759 17108111
  16. Butler J.S. Loh S.N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain Biochemistry 42 2003 2396 2403 12600206
  17. Bykov V.J. Issaeva N. Zache N. Shilov A. Hultcrantz M. Bergman J. Selivanova G. Wiman K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs J. Biol. Chem. 280 2005 30384 30391 15998635
  18. Capponcelli S. Pedrini E. Cerone M.A. Corti V. Fontanesi S. Alessio M. Bachi A. Soddu S. Ribatti D. Picci P. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation Hum. Mutat. 26 2005 94 103 15977174
  19. Chee J.L. Saidin S. Lane D.P. Leong S.M. Noll J.E. Neilsen P.M. Phua Y.T. Gabra H. Lim T.M. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9 Cell Cycle 12 2013 278 288 23255126 PMC3575457
  20. Chicas A. Molina P. Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA Biochem. Biophys. Res. Commun. 279 2000 383 390 11118296
  21. Choudhury S. Kolukula V.K. Preet A. Albanese C. Avantaggiati M.L. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle 12 2013 1022 1029 23466706 PMC3646859
  22. Coffill C.R. Muller P.A. Oh H.K. Neo S.P. Hogue K.A. Cheok C.F. Vousden K.H. Lane D.P. Blackstock W.P. Gunaratne J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion EMBO Rep. 13 2012 638 644 22653443 PMC3388785
  23. Cooks T. Pateras I.S. Tarcic O. Solomon H. Schetter A.J. Wilder S. Lozano G. Pikarsky E. Forshew T. Rosenfeld N. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer Cancer Cell 23 2013 634 646 23680148 PMC3657134
  24. Demma M. Maxwell E. Ramos R. Liang L. Li C. Hesk D. Rossman R. Mallams A. Doll R. Liu M. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 J. Biol. Chem. 285 2010 10198 10212 20124408 PMC2856225
  25. Desgrosellier J.S. Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22 20029421 PMC4383089
  26. Di Agostino S. Strano S. Emiliozzi V. Zerbini V. Mottolese M. Sacchi A. Blandino G. Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation Cancer Cell 10 2006 191 202 16959611
  27. Di Como C.J. Gaiddon C. Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells Mol. Cell. Biol. 19 1999 1438 1449 9891077 PMC116072
  28. Dittmer D. Pati S. Zambetti G. Chu S. Teresky A.K. Moore M. Finlay C. Levine A.J. Gain of function mutations in p53 Nat. Genet. 4 1993 42 46 8099841
  29. Do P.M. Varanasi L. Fan S. Li C. Kubacka I. Newman V. Chauhan K. Daniels S.R. Boccetta M. Garrett M.R. Mutant p53 cooperates with ETS2 to promote etoposide resistance Genes Dev. 26 2012 830 845 22508727 PMC3337457
  30. Dong P. Xu Z. Jia N. Li D. Feng Y. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway Mol. Cancer 8 2009 103 19917135 PMC2779797
  31. Dong P. Karaayvaz M. Jia N. Kaneuchi M. Hamada J. Watari H. Sudo S. Ju J. Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis Oncogene 2012 PMC3705163 22847613
  32. Doyle B. Morton J.P. Delaney D.W. Ridgway R.A. Wilkins J.A. Sansom O.J. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma J. Pathol. 222 2010 129 137 20662002
  33. Dumay A. Feugeas J.P. Wittmer E. Lehmann-Che J. Bertheau P. Espie M. Plassa L.F. Cottu P. Marty M. Andre F. Distinct tumor protein p53 mutants in breast cancer subgroups International journal of cancer Journal international du cancer 132 2013 1227 1231 22886769
  34. El-Hizawi S. Lagowski J.P. Kulesz-Martin M. Albor A. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins Cancer Res. 62 2002 3264 3270 12036943
  35. Esser C. Scheffner M. Höhfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation J. Biol. Chem. 280 2005 27443 27448 15911628
  36. Fontemaggi G. Dell’Orso S. Trisciuoglio D. Shay T. Melucci E. Fazi F. Terrenato I. Mottolese M. Muti P. Domany E. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis Nat. Struct. Mol. Biol. 16 2009 1086 1093 19783986
  37. Foster B.A. Coffey H.A. Morin M.J. Rastinejad F. Pharmacological rescue of mutant p53 conformation and function Science 286 1999 2507 2510 10617466
  38. Frank A.K. Pietsch E.C. Dumont P. Tao J. Murphy M.E. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3 Cancer Biol. Ther. 11 2011 740 745 21307660 PMC3100564
  39. Freed-Pastor W.A. Prives C. Mutant p53: one name, many proteins Genes Dev. 26 2012 1268 1286 22713868 PMC3387655
  40. Freed-Pastor W.A. Mizuno H. Zhao X. Langerød A. Moon S.H. Rodriguez-Barrueco R. Barsotti A. Chicas A. Li W. Polotskaia A. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway Cell 148 2012 244 258 22265415 PMC3511889
  41. Gaiddon C. Lokshin M. Ahn J. Zhang T. Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain Mol. Cell. Biol. 21 2001 1874 1887 11238924 PMC86759
  42. Gerwin B.I. Spillare E. Forrester K. Lehman T.A. Kispert J. Welsh J.A. Pfeifer A.M. Lechner J.F. Baker S.J. Vogelstein B. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1 Proc. Natl. Acad. Sci. USA 89 1992 2759 2763 1557382 PMC48742
  43. Girardini J.E. Napoli M. Piazza S. Rustighi A. Marotta C. Radaelli E. Capaci V. Jordan L. Quinlan P. Thompson A. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer Cancer Cell 20 2011 79 91 21741598
  44. Gloushankova N. Ossovskaya V. Vasiliev J. Chumakov P. Kopnin B. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes Oncogene 15 1997 2985 2989 9416842
  45. Gogna R. Madan E. Kuppusamy P. Pati U. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression J. Biol. Chem. 287 2012 2907 2914 22147694 PMC3268447
  46. Göhler T. Jäger S. Warnecke G. Yasuda H. Kim E. Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode Nucleic Acids Res. 33 2005 1087 1100 15722483 PMC549414
  47. Grugan K.D. Vega M.E. Wong G.S. Diehl J.A. Bass A.J. Wong K.K. Nakagawa H. Rustgi A.K. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion Cancer Biol. Ther. 14 2013 14 PMC3909554 23792586
  48. Gualberto A. Aldape K. Kozakiewicz K. Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control Proc. Natl. Acad. Sci. USA 95 1998 5166 5171 9560247 PMC20232
  49. Gurova K.V. Rokhlin O.W. Budanov A.V. Burdelya L.G. Chumakov P.M. Cohen M.B. Gudkov A.V. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells Cancer Res. 63 2003 2905 2912 12782597
  50. Gurtner A. Starace G. Norelli G. Piaggio G. Sacchi A. Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function J. Biol. Chem. 285 2010 14160 14169 20223820 PMC2863202
  51. Halevy O. Michalovitz D. Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities Science 250 1990 113 116 2218501
  52. Hanel W. Marchenko N. Xu S. Yu S.X. Weng W. Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis Cell Death Differ. 20 2013 898 909 23538418 PMC3679454
  53. Hsiao M. Low J. Dorn E. Ku D. Pattengale P. Yeargin J. Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness Am. J. Pathol. 145 1994 702 714 8080050 PMC1890319
  54. Huang X. Zhang Y. Tang Y. Butler N. Kim J. Guessous F. Schiff D. Mandell J. Abounader R. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy Neoplasia 15 2013 952 965 23908595 PMC3730046
  55. Jackson J.G. Lozano G. The mutant p53 mouse as a pre-clinical model Oncogene 32 2013 4325 4330 23318424
  56. Jackson E.L. Olive K.P. Tuveson D.A. Bronson R. Crowley D. Brown M. Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer Cancer Res. 65 2005 10280 10288 16288016
  57. Jackson J.G. Pant V. Li Q. Chang L.L. Quintás-Cardama A. Garza D. Tavana O. Yang P. Manshouri T. Li Y. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer Cancer Cell 21 2012 793 806 22698404 PMC3376352
  58. Jia S. Zhao L. Tang W. Luo Y. The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12 Int. J. Biol. Sci. 8 2012 596 605 22553460 PMC3341601
  59. Joerger A.C. Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants Oncogene 26 2007 2226 2242 17401432
  60. Joerger A.C. Fersht A.R. Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 77 2008 557 582 18410249
  61. Kalo E. Kogan-Sakin I. Solomon H. Bar-Nathan E. Shay M. Shetzer Y. Dekel E. Goldfinger N. Buganim Y. Stambolsky P. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species J. Cell Sci. 125 2012 5578 5586 22899716
  62. Kandoth C. McLellan M.D. Vandin F. Ye K. Niu B. Lu C. Xie M. Zhang Q. McMichael J.F. Wyczalkowski M.A. Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339 24132290 PMC3927368
  63. Kawamata H. Omotehara F. Nakashiro K. Uchida D. Shinagawa Y. Tachibana M. Imai Y. Fujimori T. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage Int. J. Oncol. 30 2007 1089 1097 17390010
  64. King S.I. Purdie C.A. Bray S.E. Quinlan P.R. Jordan L.B. Thompson A.M. Meek D.W. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom Breast Cancer Res. 14 2012 R40 22405092 PMC3446374
  65. Kravchenko J.E. Ilyinskaya G.V. Komarov P.G. Agapova L.S. Kochetkov D.V. Strom E. Frolova E.I. Kovriga I. Gudkov A.V. Feinstein E. Chumakov P.M. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway Proc. Natl. Acad. Sci. USA 105 2008 6302 6307 18424558 PMC2327210
  66. Lang G.A. Iwakuma T. Suh Y.A. Liu G. Rao V.A. Parant J.M. Valentin-Vega Y.A. Terzian T. Caldwell L.C. Strong L.C. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 119 2004 861 872 15607981
  67. Lányi A. Deb D. Seymour R.C. Ludes-Meyers J.H. Subler M.A. Deb S. ‘Gain of function’ phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain Oncogene 16 1998 3169 3176 9671396
  68. Lee M.K. Teoh W.W. Phang B.H. Tong W.M. Wang Z.Q. Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo Cancer Cell 22 2012 751 764 23238012
  69. Lehmann B.D. Pietenpol J.A. Targeting mutant p53 in human tumors Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30 2012 3648 3650 22965952
  70. Leroy B. Fournier J.L. Ishioka C. Monti P. Inga A. Fronza G. Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis Nucleic Acids Res. 41 Database issue 2013 D962 D969 23161690 PMC3531172
  71. Li R. Sutphin P.D. Schwartz D. Matas D. Almog N. Wolkowicz R. Goldfinger N. Pei H. Prokocimer M. Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways Oncogene 16 1998 3269 3277 9681825
  72. Li D. Marchenko N.D. Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis Cell Death Differ. 18 2011 1904 1913 21637290 PMC3170683
  73. Li D. Marchenko N.D. Schulz R. Fischer V. Velasco-Hernandez T. Talos F. Moll U.M. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells Mol. Cancer Res. 9 2011 577 588 21478269 PMC3097033
  74. Lim L.Y. Vidnovic N. Ellisen L.W. Leong C.O. Mutant p53 mediates survival of breast cancer cells Br. J. Cancer 101 2009 1606 1612 19773755 PMC2778523
  75. Liu E.Y. Ryan K.M. Autophagy and cancer—issues we need to digest J. Cell Sci. 125 2012 2349 2358 22641689
  76. Liu K. Ling S. Lin W.C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73 Mol. Cell. Biol. 31 2011 4464 4481 21930790 PMC3209258
  77. Liu X. Wilcken R. Joerger A.C. Chuckowree I.S. Amin J. Spencer J. Fersht A.R. Small molecule induced reactivation of mutant p53 in cancer cells Nucleic Acids Res. 41 2013 6034 6044 23630318 PMC3695503
  78. Loging W.T. Reisman D. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53 Cancer Epidemiol Biomarkers Prev. 8 1999 1011 1016 10566557
  79. Loh S.N. The missing zinc: p53 misfolding and cancer Metallomics: integrated biometal science 2 2010 442 449 21072344
  80. Lu X. Liu D.P. Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis Oncogene 32 2013 2900 2906 22824795 PMC3586389
  81. Lukashchuk N. Vousden K.H. Ubiquitination and degradation of mutant p53 Mol. Cell. Biol. 27 2007 8284 8295 17908790 PMC2169174
  82. Madar S. Harel E. Goldstein I. Stein Y. Kogan-Sakin I. Kamer I. Solomon H. Dekel E. Tal P. Goldfinger N. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta PLoS ONE 8 2013 e61353 23630584 PMC3632588
  83. Maslon M.M. Hupp T.R. Drug discovery and mutant p53 Trends Cell Biol. 20 2010 542 555 20656489
  84. Matas D. Sigal A. Stambolsky P. Milyavsky M. Weisz L. Schwartz D. Goldfinger N. Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis EMBO J. 20 2001 4163 4172 11483519 PMC149170
  85. Mizushima N. Levine B. Cuervo A.M. Klionsky D.J. Autophagy fights disease through cellular self-digestion Nature 451 2008 1069 1075 18305538 PMC2670399
  86. Morselli E. Tasdemir E. Maiuri M.C. Galluzzi L. Kepp O. Criollo A. Vicencio J.M. Soussi T. Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy Cell Cycle 7 2008 3056 3061 18818522
  87. Morton J.P. Timpson P. Karim S.A. Ridgway R.A. Athineos D. Doyle B. Jamieson N.B. Oien K.A. Lowy A.M. Brunton V.G. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer Proc. Natl. Acad. Sci. USA 107 2010 246 251 20018721 PMC2806749
  88. Muller P.A. Vousden K.H. p53 mutations in cancer Nat. Cell Biol. 15 2013 2 8 23263379
  89. Muller P.A. Caswell P.T. Doyle B. Iwanicki M.P. Tan E.H. Karim S. Lukashchuk N. Gillespie D.A. Ludwig R.L. Gosselin P. Mutant p53 drives invasion by promoting integrin recycling Cell 139 2009 1327 1341 20064378
  90. Muller P.A. Trinidad A.G. Timpson P. Morton J.P. Zanivan S. van den Berghe P.V. Nixon C. Karim S.A. Caswell P.T. Noll J.E. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion Oncogene 32 2012 1252 1265 22580601 PMC3592945
  91. Murphy K.L. Dennis A.P. Rosen J.M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model FASEB journal: official publication of the Federation of American Societies for Experimental Biology 14 2000 2291 2302 11053251
  92. Narendran A. Ganjavi H. Morson N. Connor A. Barlow J.W. Keystone E. Malkin D. Freedman M.H. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth Exp. Hematol. 31 2003 693 701 12901974
  93. Neilsen P.M. Noll J.E. Mattiske S. Bracken C.P. Gregory P.A. Schulz R.B. Lim S.P. Kumar R. Suetani R.J. Goodall G.J. Callen D.F. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155 Oncogene 32 2012 2992 3000 22797073
  94. Nguyen C.H. Lang B.J. Chai R.C. Vieusseux J.L. Kouspou M.M. Price J.T. Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status Biochem. J. 452 2013 321 329 23510323
  95. Noll J.E. Jeffery J. Al-Ejeh F. Kumar R. Khanna K.K. Callen D.F. Neilsen P.M. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11 Oncogene 31 2012 2836 2848 21986947
  96. Ostman A. Augsten M. Cancer-associated fibroblasts and tumor growth—bystanders turning into key players Curr. Opin. Genet. Dev. 19 2009 67 73 19211240
  97. Patocs A. Zhang L. Xu Y. Weber F. Caldes T. Mutter G.L. Platzer P. Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases N. Engl. J. Med. 357 2007 2543 2551 18094375
  98. Pietras K. Ostman A. Hallmarks of cancer: interactions with the tumor stroma Exp. Cell Res. 316 2010 1324 1331 20211171
  99. Pintus S.S. Ivanisenko N.V. Demenkov P.S. Ivanisenko T.V. Ramachandran S. Kolchanov N.A. Ivanisenko V.A. The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain J. Biomol. Struct. Dyn. 31 2013 78 86 22803791
  100. Pohl U. Wagenknecht B. Naumann U. Weller M. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 9 1999 29 37 10352342
  101. Preuss U. Kreutzfeld R. Scheidtmann K.H. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation Int. J. Cancer 88 2000 162 171 11004663
  102. Puca R. Nardinocchi L. Bossi G. Sacchi A. Rechavi G. Givol D. D’Orazi G. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc Exp. Cell Res. 315 2009 67 75 18996371
  103. Puca R. Nardinocchi L. Porru M. Simon A.J. Rechavi G. Leonetti C. Givol D. D’Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs Cell Cycle 10 2011 1679 1689 21508668
  104. Pugacheva E.N. Ivanov A.V. Kravchenko J.E. Kopnin B.P. Levine A.J. Chumakov P.M. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil Oncogene 21 2002 4595 4600 12096336
  105. Quante T. Otto B. Brázdová M. Kejnovská I. Deppert W. Tolstonog G.V. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity Cell Cycle 11 2012 3290 3303 22894900 PMC3466528
  106. Restle A. Färber M. Baumann C. Böhringer M. Scheidtmann K.H. Müller-Tidow C. Wiesmüller L. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants Nucleic Acids Res. 36 2008 5362 5375 18697815 PMC2532731
  107. Rieber M. Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells Biochem. Pharmacol. 84 2012 1563 1570 22982566
  108. Rodriguez O.C. Choudhury S. Kolukula V. Vietsch E.E. Catania J. Preet A. Reynoso K. Bargonetti J. Wellstein A. Albanese C. Avantaggiati M.L. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy Cell Cycle 11 2012 4436 4446 23151455 PMC3552926
  109. Roger L. Jullien L. Gire V. Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells J. Cell Sci. 123 2010 1295 1305 20332115
  110. Sarig R. Rivlin N. Brosh R. Bornstein C. Kamer I. Ezra O. Molchadsky A. Goldfinger N. Brenner O. Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells J. Exp. Med. 207 2010 2127 2140 20696700 PMC2947075
  111. Sauer L. Gitenay D. Vo C. Baron V.T. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells Oncogene 29 2010 2628 2637 20190820 PMC2865566
  112. Schilling T. Kairat A. Melino G. Krammer P.H. Stremmel W. Oren M. Müller M. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma Biochem. Biophys. Res. Commun. 394 2010 817 823 20233581
  113. Scian M.J. Stagliano K.E. Deb D. Ellis M.A. Carchman E.H. Das A. Valerie K. Deb S.P. Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes Oncogene 23 2004 4430 4443 15077194
  114. Scian M.J. Stagliano K.E. Ellis M.A. Hassan S. Bowman M. Miles M.F. Deb S.P. Deb S. Modulation of gene expression by tumor-derived p53 mutants Cancer Res. 64 2004 7447 7454 15492269
  115. Shi X.B. Nesslinger N.J. Deitch A.D. Gumerlock P.H. deVere White R.W. Complex functions of mutant p53 alleles from human prostate cancer Prostate 51 2002 59 72 11920959
  116. Singh S. Singh P.P. Statin a day keeps cancer at bay World journal of clinical oncology 4 2013 43 46 23696961 PMC3659262
  117. Smith P.D. Crossland S. Parker G. Osin P. Brooks L. Waller J. Philp E. Crompton M.R. Gusterson B.A. Allday M.J. Crook T. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions Oncogene 18 1999 2451 2459 10229196
  118. Solomon H. Buganim Y. Kogan-Sakin I. Pomeraniec L. Assia Y. Madar S. Goldstein I. Brosh R. Kalo E. Beatus T. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature J. Cell Sci. 125 2012 3144 3152 22427690
  119. Sonego M. Schiappacassi M. Lovisa S. Dall’Acqua A. Bagnoli M. Lovat F. Libra M. D’Andrea S. Canzonieri V. Militello L. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer EMBO molecular medicine 5 2013 707 722 23610071 PMC3662314
  120. Song H. Hollstein M. Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM Nat. Cell Biol. 9 2007 573 580 17417627
  121. Stambolsky P. Tabach Y. Fontemaggi G. Weisz L. Maor-Aloni R. Siegfried Z. Shiff I. Kogan I. Shay M. Kalo E. Modulation of the vitamin D3 response by cancer-associated mutant p53 Cancer Cell 17 2010 273 285 20227041 PMC2882298
  122. Strano S. Fontemaggi G. Costanzo A. Rizzo M.G. Monti O. Baccarini A. Del Sal G. Levrero M. Sacchi A. Oren M. Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities J. Biol. Chem. 277 2002 18817 18826 11893750
  123. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat. Rev. Drug Discov. 9 2010 643 660 20671765
  124. Su X. Chakravarti D. Cho M.S. Liu L. Gi Y.J. Lin Y.L. Leung M.L. El-Naggar A.K. Creighton C.J. Suraokar M.B. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs Nature 467 2010 986 990 20962848 PMC3055799
  125. Suh Y.A. Post S.M. Elizondo-Fraire A.C. Maccio D.R. Jackson J.G. El-Naggar A.K. Van Pelt C. Terzian T. Lozano G. Multiple stress signals activate mutant p53 in vivo Cancer Res. 71 2011 7168 7175 21983037 PMC3320147
  126. Sun Y. Nakamura K. Wendel E. Colburn N. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma Proc. Natl. Acad. Sci. USA 90 1993 2827 2831 8464896 PMC46189
  127. Tan E.H. Morton J.P. Timpson P. Tucci P. Melino G. Flores E.R. Sansom O.J. Vousden K.H. Muller P.A. Functions of TAp63 and p53 in restraining the development of metastatic cancer Oncogene 2013 PMC4181588 23873029
  128. Trepel M. Groscurth P. Malipiero U. Gulbins E. Dichgans J. Weller M. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer J. Neurooncol. 39 1998 19 32 9760067
  129. Trinidad A.G. Muller P.A. Cuellar J. Klejnot M. Nobis M. Valpuesta J.M. Vousden K.H. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity Mol. Cell 50 2013 805 817 23747015 PMC3699784
  130. Tsang W.P. Ho F.Y. Fung K.P. Kong S.K. Kwok T.T. p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis International journal of cancer Journal international du cancer 114 2005 331 336 15578696
  131. Vakifahmetoglu-Norberg H. Kim M. Xia H.G. Iwanicki M.P. Ofengeim D. Coloff J.L. Pan L. Ince T.A. Kroemer G. Brugge J.S. Yuan J. Chaperone-mediated autophagy degrades mutant p53 Genes Dev. 27 2013 1718 1730 23913924 PMC3744729
  132. Vaughan C.A. Frum R. Pearsall I. Singh S. Windle B. Yeudall A. Deb S.P. Deb S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells Biochem. Biophys. Res. Commun. 428 2012 6 10 22989750 PMC4731231
  133. Vaughan C.A. Singh S. Windle B. Sankala H.M. Graves P.R. Andrew Yeudall W. Deb S.P. Deb S. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity Arch. Biochem. Biophys. 518 2012 79 88 22198284 PMC3272778
  134. Verhaegh G.W. Parat M.O. Richard M.J. Hainaut P. Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc Mol. Carcinog. 21 1998 205 214 9537652
  135. Walerych D. Napoli M. Collavin L. Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer Carcinogenesis 33 2012 2007 2017 22822097 PMC3483014
  136. Wang X. Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach BMC Med. Genomics 6 2013 30 24025726 PMC3847148
  137. Wang Y. Suh Y.A. Fuller M.Y. Jackson J.G. Xiong S. Terzian T. Quintás-Cardama A. Bankson J.A. El-Naggar A.K. Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation J. Clin. Invest. 121 2011 893 904 21285512 PMC3049366
  138. Wang W. Cheng B. Miao L. Mei Y. Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression Cell Death Dis. 4 2013 e574 23559009 PMC3642368
  139. Wang X. Chen J.X. Liu J.P. You C. Liu Y.H. Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide Ann. Surg. Oncol. 2013 Published online November 19, 2013 24248532
  140. Weisz L. Zalcenstein A. Stambolsky P. Cohen Y. Goldfinger N. Oren M. Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function Cancer Res. 64 2004 8318 8327 15548700
  141. Weisz L. Oren M. Rotter V. Transcription regulation by mutant p53 Oncogene 26 2007 2202 2211 17401429
  142. Wiman K.G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient Oncogene 29 2010 4245 4252 20498645
  143. Wong R.P. Tsang W.P. Chau P.Y. Co N.N. Tsang T.Y. Kwok T.T. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther. 6 2007 1054 1061 17363498
  144. Xie T.X. Zhou G. Zhao M. Sano D. Jasser S.A. Brennan R.G. Myers J.N. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells Laryngoscope 123 2013 1416 1423 23625637 PMC3664100
  145. Yan W. Chen X. Identification of GRO1 as a critical determinant for mutant p53 gain of function J. Biol. Chem. 284 2009 12178 12187 19258312 PMC2673286
  146. Yan W. Chen X. Characterization of functional domains necessary for mutant p53 gain of function J. Biol. Chem. 285 2010 14229 14238 20212049 PMC2863234
  147. Yan W. Liu G. Scoumanne A. Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations Cancer Res. 68 2008 6789 6796 18701504 PMC2597213
  148. Yeudall W.A. Vaughan C.A. Miyazaki H. Ramamoorthy M. Choi M.Y. Chapman C.G. Wang H. Black E. Bulysheva A.A. Deb S.P. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration Carcinogenesis 33 2012 442 451 22114072
  149. Yi L. Lu C. Hu W. Sun Y. Levine A.J. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation Cancer Res. 72 2012 5635 5645 22964580
  150. Yi Y.W. Kang H.J. Kim H.J. Kong Y. Brown M.L. Bae I. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells Oncotarget 4 2013 984 994 23846322 PMC3759676
  151. Yoshikawa K. Hamada J. Tada M. Kameyama T. Nakagawa K. Suzuki Y. Ikawa M. Hassan N.M. Kitagawa Y. Moriuchi T. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells Biomed. Res. 31 2010 401 411 21187651
  152. Yu X. Vazquez A. Levine A.J. Carpizo D.R. Allele-specific p53 mutant reactivation Cancer Cell 21 2012 614 625 22624712 PMC3366694
  153. Zache N. Lambert J.M. Rökaeus N. Shen J. Hainaut P. Bergman J. Wiman K.G. Bykov V.J. Mutant p53 targeting by the low molecular weight compound STIMA-1 Mol. Oncol. 2 2008 70 80 19383329 PMC5527782
  154. Zalcenstein A. Weisz L. Stambolsky P. Bar J. Rotter V. Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 Oncogene 25 2006 359 369 16170349
  155. Zerdoumi Y. Aury-Landas J. Bonaïti-Pellié C. Derambure C. Sesboüé R. Renaux-Petel M. Frebourg T. Bougeard G. Flaman J.M. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients Hum. Mutat. 34 2013 453 461 23172776
  156. Zhang Y. Yan W. Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions J. Biol. Chem. 286 2011 16218 16228 21454711 PMC3091229
  157. Zhu H. Mao Q. Lin Y. Yang K. Xie L. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells Med. Oncol. 28 Suppl 1 2011 S381 S387 20857345
  158. Zhu H.B. Yang K. Xie Y.Q. Lin Y.W. Mao Q.Q. Xie L.P. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells World J. Surg. Oncol. 11 2013 22 23356234 PMC3565885

Cited by

Sorted by citations

Authors
Muller, P. A. J., & Vousden, K. H.
Affiliations
  • Medical Research Council (GB)
  • Cancer Research UK Scotland Institute (GB)
Corresponding author
  • Muller, Patricia A.J.
  • Vousden, Karen H.
ORCID
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2014-03
Volume
25
Issue
3
Pages
304-317
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/j.ccr.2014.01.021
PMC
PMC3970583
OpenAlex
W1995068068
Cited by
1,545
References
14
Citations by year
2026: 69 · 2025: 74 · 2024: 90 · 2023: 113 · 2022: 139 · 2021: 140 · 2020: 166 · 2019: 145 · 2018: 176 · 2017: 157 · 2016: 126 · 2015: 108 · 2014: 38 · 2012: 1
FWCI
16.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Cell (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Durham Research Online (Durham University) (submittedVersion, cc-by)
  • Research Explorer (The University of Manchester) (submittedVersion)
Funders
  • Cancer Research Society
  • Wellcome Trust (101242)
  • Cancer Research UK (18274)
  • Royal Society
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
mutant p53, TP53 mutation, gain-of-function p53, malignant progression, cancer therapy
MeSH terms
Animals, Humans, Mutation, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review